Everest Medicines Acquires Exclusive Rights to Novel Biologic for Eye Disorders
Everest Medicines has acquired an exclusive license to develop, manufacture, and commercialize VIS-101, a novel bifunctional biologic for serious eye disorders, in Greater China and other Asian countries.
Partnership Details
The license was acquired from Visara, Inc., a subsidiary of NovaBridge Biosciences, listed on the Nasdaq Global Market under the symbol "NBP".
- Exclusive rights in Greater China, Singapore, South Korea, and certain Southeast Asian countries
- Upfront payment of US$7 million (approximately RMB49.7 million)
- Reimbursement of up to RMB24.0 million for prior expenses
- Potential payments of up to US$89 million
This collaboration marks Everest's strategic expansion into ophthalmology, a high-potential therapeutic area.
Author's summary: Everest Medicines expands into ophthalmology with exclusive license to VIS-101.
More News
- Spillcontrol – Spill Control
- Where the Chefs Eat: Skye McAlpine’s Venice
- Warriors 99-94 Cavaliers (Dec 6, 2025) Game Recap
- Is London The Top City In The World For This Cuisine? These Chefs Say Yes
- Solidarity on Trial in Greece
- Restaurants, hôtels, bars, caves et commerces de … - Paris
- Nobel Prize banquet chefs and pastry chef 2025
- Oil spills and technological cooperation for their prevention
- The first week of testimony in Brian Walshe’s murder trial is over. Here are takeaways from Day 5
- Spill and pollution response